SPOTLIGHT -
Novel Oral NMDA Receptor Antagonist Approved for Treatment of MDD
Dextromethorphan HBr -bupropion HCl extended-release tablets for the treatment of major depressive disorder just became FDA approved.
COVID-19: A Direct Viral Attack on the Brain
What are the long term psychiatric and neuropsychiatric complications of COVID-19?
The Importance of Managing Psychiatric Disorders During Pregnancy and Postpartum
Treating women of reproductive age who have depression can be difficult. Here’s an overview on the subject from the 2022 Annual Psychiatric Times™ World CME Conference.
Trauma in Your DNA: Educator of the Year Lecture
Can we inherit our parents’ trauma? Research points to yes.
Childhood Trauma: 10 Tips for Screening and More
How do you screen for childhood trauma? One doctor at the 2022 Annual Psychiatric Times™ World CME Conference in San Diego, one doctor shared his most helpful tips.
Caution Ahead: FDA Asks for More Info on Expanded Use of Antipsychotic Drug
Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.
“A New and Differentiated Approach for Schizophrenia”: Positive Results for Phase 3 Trial
This novel schizophrenia treatment showed positive results in a phase 3 trial evaluating efficacy, safety, and tolerability.
New Review Calls Antidepressants Into Question—But Does the Review Have Merit?
A new review shows that there is no convincing evidence that depression is caused low levels of serotonin.
Loan Repayment Program to Help Ease Student Debt Burden for Psychiatrists
Do you qualify for student loan forgiveness?
Reducing Heavy Drinking Days: Positive Results From Trial for Medication Treating Alcohol Use Disorder
Positive results from the phase 3 trial of AD04 show a 79% reduction in heavy drinking.
Upcoming Release of Phase 3 Trial Results for Medication Treating Alcohol Use Disorder
New results are coming for AD04, a potential treatment for patients with alcohol use disorder.
New 988 Suicide Hotline: Hope or Hype?
The new suicide hotline is launching July 16. Are we ready for it?
4 Recommendations for Disability Inclusion in Psychedelic Therapy Research
How can psychedelic research incorporate disability inclusion into future work?
The Overturning of Roe v. Wade
What do psychiatrists think of the overturning of Roe v. Wade?
Narcolepsy: Making the Right Diagnosis
In this installment of the Around the Practice custom video program, doctors discussed management of narcolepsy.
Mental Health App Collaborates With the American Foundation for Suicide Prevention
The American Foundation for Suicide Prevention collaborates with Most Days, a mental health app, to provide suicide prevention expertise and content. Learn more about the partnership here.
Positive Results From SKYLARK for Patients With Postpartum Depression
Zuranolone, an investigational oral drug being evaluated in women with postpartum depression, sees positive phase 3 study results.
On Thin Ice: Competitive Sports & Youth Mental Health
What will society do to children in order to make them win? What should be sacrificed in the name of competition? How much pressure is too much? And how do we pick up the pieces when young athletes are pushed too far?
Positive Results for Dextromethorphan-Bupropion ASCEND Phase 2 Clinical Trial
Axsome Therapeutics announced the robust antidepressant efficacy demonstrated in this latest study.
Must Sees in New Orleans: Things to Check Out During 2022 APA
If you're attending APA 2022 in New Orleans, here are some other things to check out in the city.
The Effect of Socioeconomic Factors on Depression Treatment
Home environments have a clear impact on depression treatment outcomes.
Rolling NDA Submission of Zuranolone for Treatment of Major Depressive Disorder
Zuranolone, a drug for the treatment of major depressive disorder and postpartum disorder, is on a rolling submission of a new drug application.
The Relationship Between Unhealthy Eating and ADHD in Children
A recent study found a negative association between children with ADHD and health eating patterns.
APhA Conference Addresses Depression, Benzos
Catch up on all the latest from the American Pharmacists Association (APhA) Annual Meeting & Exposition.
Naloxone as a Tool to Fight the Opioid Epidemic
If you missed out on the custom Around the Practice video program on naloxone, we've got you covered. Read a recap here.
Hyperprolactinemia and Antipsychotic Therapy in Patients With Schizophrenia
A recent study examined hyperprolactinemia and antipsychotic therapy in patients with schizophrenia and Hashimoto's thyroiditis.
New Approval for Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder
The FDA has approved dexmedetomidine sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Predicting Depression and Alzheimer Disease Through Major Depressive Disorder Risk Factors
Individuals with depression may be at a greater risk to develop late-onset Alzheimer disease, but a new study suggests depression onset may help predict Alzheimer disease.
Psychiatric Care in the US: Are We Facing a Crisis?
What US state has the best mental health care?
World Bipolar Day: The Birthday of Vincent Van Gogh
Today is World Bipolar Day! Celebrate with the freshest clinical pearls on bipolar disorder that Psychiatric Times has to offer.